Infant nutrition company Biotime is just the latest of such companies within China to modify its business practices following the announcement of an antirust investigation into the sector by Chinese authorities. The nation’s National Reform and Development Commission launched a probe into various makers of infant formula for suspicion of price-fixing. Biostime announced Tuesday plans to revise contracts with its distributors, according to reports. The case is particular, however, as reports say the price-fixing probe focuses on foreign companies in the market; Biostime is a domestic company. The company’s wholly-owned Chinese subsidiary is currently under investigation by the NDRC.
Featured News
DOJ Considers Reviving Collaboration Guidelines to Clarify Antitrust Rules
Mar 25, 2026 by
CPI
JetBlue Weighs Sale to Rival Airlines Amid Strategic Review
Mar 25, 2026 by
CPI
Chile Approves Joint Codelco–Anglo American Copper Project
Mar 25, 2026 by
CPI
Bernie Sanders Unveils Bill to Ban Data Centers Until Congress Passes AI Regulation
Mar 25, 2026 by
CPI
CFTC Unveils New Task Force to Focus on AI, Crypto, Prediction Markets
Mar 25, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Competitor Collaborations
Mar 26, 2026 by
CPI
Between Scylla and Charybdis – Navigating Transatlantic Antitrust Currents
Mar 26, 2026 by
Tilman Kuhn & Niklas Brüggemann
Cartel Enforcement Moves Into the Labor Market: Trends and Implications
Mar 26, 2026 by
Andreas Kafetzopoulos & Caroline Janssens
Rethinking Buy-Side Antitrust “Group Boycotts”
Mar 26, 2026 by
Craig Falls & Brendan McGuire
Positive Collaborations: The Tools Available to Competition Authorities to Encourage Beneficial Interactions Between Competitors
Mar 26, 2026 by
Rona Bar-Isaac & Thomas Withers